A Phase 2, monocentric, prospective, nonrandomized, open-label, experimental study to evaluate efficacy and safety of intrabronchial instillation of liposomal Amphotericin B in patients with simple pulmonary aspergilloma.
This study is looking into a new treatment for a lung infection called simple aspergilloma. This infection is caused by a type of fungus. The treatment involves giving a medicine called Amphotericin B directly into the lungs through a bronchoscope. This is a tube that doctors can use to look into your lungs. The main aim is to see how much the infection shrinks after treatment and to make sure the treatment is safe for patients. Researchers will also check for any side effects and how patients feel overall. This is an early-stage study, meaning it’s one of the first times this treatment method is being tested in people with this condition.
At a glance
What is this study about?
This study is about finding a better way to treat a lung condition called simple aspergilloma. This condition happens when a ball of fungus, often called a 'fungus ball' or 'mycetoma,' grows inside a cavity in the lung. It's not the same as a widespread chest infection, but rather a localised problem. The current ways to treat this can sometimes be difficult or not fully effective, so doctors are always looking for new and improved methods.
The medicine being tested is called Amphotericin B. It's a standard antifungal medication, but in this study, it's being given in a special way. It's put into tiny fat bubbles (called liposomes) and then delivered directly into the lungs using a procedure called bronchoscopy. The idea behind this is to deliver the medicine precisely where it's needed, hoping it will be more effective and have fewer side effects than if given in other ways.
The main goal of the study is to see how well this new method works at shrinking the fungus ball in the lung. They will measure the size of the fungus ball before and after treatment to see if it gets smaller. They also want to carefully watch for any side effects and understand how safe this treatment approach is for patients. By studying these things, doctors hope to gather important information that could lead to a new and effective treatment option for people with simple aspergilloma.
Key takeaways
- This study explores a new way to treat lung fungal infections (simple aspergilloma).
- It aims to deliver medicine directly into the lungs for better effect and safety.
- Researchers will check if the treatment shrinks the fungus and if there are side effects.
- Participation involves special lung procedures and regular health checks.
- This is an early-stage study, trying a new method for the first time in patients.
Who may be eligible?
To be considered for this study, you would need to have been diagnosed with a condition called 'simple aspergilloma.' This means you have a specific type of fungal growth in your lung. You need to be at least 18 years old; there isn't an upper age limit mentioned.
Both men and women can take part in this study. The medical team will carefully review your health to make sure this study is right for you and that taking part would be safe.
The study is only for those who fit specific health requirements to ensure the results are clear and relevant to the condition being studied.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I at least 18 years old?
- Have I been diagnosed with 'simple aspergilloma'?
- Am I open to receiving medication directly into my lungs via a bronchoscope?
- Am I able to attend regular appointments and tests for the study?
What does participation involve?
If you decide to take part in this study, the doctors and nurses will closely monitor your health. You will receive the study medication, which is Amphotericin B, delivered directly into your lungs through a procedure called a bronchoscopy. This involves a thin, flexible tube being gently passed into your airways while you are usually given medication to help you relax.
Throughout the study, you will have regular assessments. These will include imaging scans, like X-rays or CT scans, to measure the size of your aspergilloma. You will also have blood tests and other check-ups to monitor your general health and look for any side effects. You might also be asked to complete questionnaires, like the COPD Assessment Test (CAT), to describe how you are feeling. The exact number of visits and the total length of your participation would be explained in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedLatvia
Common questions
What is simple pulmonary aspergilloma?
It's a type of lung infection caused by a fungus, where a 'fungus ball' or 'mycetoma' forms inside a hole or cavity in your lung.
What is Amphotericin B?
It's a strong medicine used to treat serious fungal infections. In this study, it's being delivered in a special way.
What does 'intrabronchial instillation' mean?
It means the medicine is put directly into your airways and lungs using a special tube called a bronchoscope.
Will I know if the treatment is working?
Doctors will take scans of your lungs before and after treatment to see if the fungus ball has shrunk.
Can I leave the study at any time?
Yes, you can choose to stop participating in the study at any point without it affecting your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.